Illumina Reports Financial Results for Second Quarter of Fiscal Year 2013
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2013
Raises Fiscal Year 2013 Guidance
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NAS: ILMN) today announced its financial results for the second quarter of 2013.
Second quarter 2013 results:
Revenue of $346 million, a 23% increase compared to $281 million in the second quarter of 2012
GAAP net income for the quarter of $36 million, or $0.26 per diluted share, compared to $23 million, or $0.18 per diluted share, for the second quarter of 2012
Non-GAAP net income for the quarter of $60 million, or $0.43 per diluted share, compared to $53 million, or $0.40 per diluted share, for the second quarter of 2012 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures)
Cash flow from operations of $89 million and free cash flow of $77 million for the quarter
Gross margin in the second quarter of 2013 was 64.6% compared to 68.8% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangible assets, and legal contingencies, non-GAAP gross margin was 69.5% for the second quarter of 2013 compared to 70.9% in the prior year period.
Research and development (R&D) expenses for the second quarter of 2013 were $67.6 million compared to $71.2 million in the second quarter of 2012. R&D expenses included $9.0 million and $7.7 million of non-cash stock compensation expense in the second quarters of 2013 and 2012, respectively. Excluding these charges, contingent compensation, and impairment of in-process R&D, R&D expenses as a percentage of revenue were 17.0% compared to 14.7% in the prior year period.
Selling, general and administrative (SG&A) expenses for the second quarter of 2013 were $88.7 million compared to $68.5 million for the second quarter of 2012. SG&A expenses included $13.9 million and $14.3 million of non-cash stock compensation expense in the second quarters of 2013 and 2012, respectively. Excluding these charges, contingent compensation, and amortization of acquired intangible assets, SG&A expenses as a percentage of revenue were 20.3% compared to 19.4% in the prior year period.
Depreciation and amortization expenses were $23.3 million and capital expenditures were $11.5 million during the second quarter of 2013. The Company ended the second quarter of 2013 with $1.13 billion in cash, cash equivalents and short-term investments, compared to $1.35 billion as of December 30, 2012.
"We are very pleased with our operational execution for the first half of 2013 and the resulting record financial performance," said Illumina's President and Chief Executive Officer Jay Flatley. "Our business demonstrated strong trends globally and our 2013 strategic initiatives for robust long-term growth are progressing as planned. As a result we are raising our expectations for 2013 financial performance."
Updates since our last earnings release:
Launched the full commercial availability of BaseSpace® Apps, which includes an e-commerce system that allows customers to quickly and easily purchase Illumina and third-party bioinformatics applications
Applied the CE mark to the MiSeqDx™ Cystic Fibrosis System
Published clinical laboratory performance data for the verifi® prenatal test
Announced an agreement with Teva Pharmaceutical Industries and the MOR Institute for Medical Data to commercialize the verifi® prenatal test in Israel
Launched Phasing Analysis Service for Human Whole-Genome Sequencing empowering gene mapping studies which provide a more comprehensive view of genomic variation
Announced that HistoGenetics, a leader in high-resolution sequencing-based human leukocyte antigen (HLA) testing services, selected the MiSeq system for use in its CLIA laboratory
Acquired Advanced Liquid Logic, a leading provider of liquid handling solutions
Announced collaborations with leading providers of liquid handling robotic platforms to develop automation methods for TruSeq® and Nextera® Sample Preparation kits
Repurchased $25 million of common stock under our previously announced share repurchase program
Retired 3 million warrants for $125 million on July 18, 2013
Financial outlook and guidance
The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and Non-GAAP financial measures.
For fiscal 2013 the Company is projecting approximately 20% revenue growth and non-GAAP earnings per fully diluted share of $1.68 to $1.72, including the impact of the Verinata and Advanced Liquid Logic acquisitions. These projections assume full year non-GAAP gross margin of approximately 69.5%, a pro forma tax rate of approximately 30% and stock compensation expense of approximately $105 million. Full-year weighted average diluted shares outstanding, for the measurement of pro forma amounts, is expected to be approximately 138 million shares assuming the current stock price.
Quarterly conference call information
The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, July 23, 2013. Interested parties may listen to the call by dialing 888.680.0879 (passcode: 22024538), or if outside North America by dialing 1.617.213.4856 (passcode: 22024538). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.
A replay of the conference call will be available from 4:00 pm Pacific Time (7:00 pm Eastern Time) on July 23, 2013 through July 30, 2013 by dialing 888.286.8010 (passcode: 66585327), or if outside North America by dialing 1.617.801.6888 (passcode: 66585327).
Statement regarding use of non-GAAP financial measures
The Company reports non-GAAP results for diluted net income per share, net income, gross margins, operating expenses, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
The Company's financial measures under GAAP include substantial charges related to stock compensation expense, legal contingencies, amortization expense related to acquired intangible assets, non-cash interest expense associated with the company's convertible debt instruments that may be settled in cash, costs related to the unsolicited tender offer for the company's stock, acquisition related expense, and others that are listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this press release. Per share amounts also include the double dilution associated with the accounting treatment of the Company's 0.625% convertible senior notes outstanding and the corresponding call option overlay. Management believes that presentation of operating results that excludes these items and per share double dilution provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing the Company's past and future operating performance.
The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.
Use of forward-looking statements
This release contains projections, information about our financial outlook, earnings guidance, and other forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to develop and commercialize further our sequencing, array, PCR, and consumables technologies and to deploy new products and applications, and expand the markets, for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; (iv) challenges inherent in developing, manufacturing, and launching new products and services; and (v) our ability to maintain our revenue and profitability during periods of research funding reduction or uncertainty and adverse economic and business conditions, including as a result of slowing economic growth in the United States or worldwide, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current financial quarter.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its applications, paving the way for molecular medicine and ultimately transforming healthcare.
Illumina, Inc. | |||||||
Condensed Consolidated Balance Sheets | |||||||
(In thousands) | |||||||
June 30, 2013 | December 30, 2012 | ||||||
ASSETS | (unaudited) | ||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 783,611 | $ | 433,981 | |||
Short-term investments | 345,852 | 916,223 | |||||
Accounts receivable, net | 207,413 | 214,975 | |||||
Inventory | 168,070 | 158,718 | |||||
Deferred tax assets, current portion | 84,887 | 30,451 | |||||
Prepaid expenses and other current assets | 56,558 | 32,700 | |||||
Total current assets | 1,646,391 | 1,787,048 | |||||
Property and equipment, net | 187,362 | 166,167 | |||||
Goodwill | 596,588 | 369,327 | |||||
Intangible assets, net | 304,469 | 130,196 | |||||
Deferred tax assets, long-term portion | 9,715 | 40,183 | |||||
Other assets | 78,677 | 73,164 | |||||
Total assets | $ | 2,823,202 | $ | 2,566,085 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 67,648 | $ | 65,727 | |||
Accrued liabilities | 198,788 | 201,877 | |||||
Accrued legal contingencies | 122,713 | - | |||||
Long-term debt, current portion | 29,731 | 36,967 | |||||
Total current liabilities | 418,880 | 304,571 | |||||
Long-term debt | 822,169 | 805,406 | |||||
Other long-term liabilities | 192,167 | 134,369 | |||||
Conversion option subject to cash settlement | 1,394 | 3,158 | |||||
Stockholders' equity | 1,388,592 | 1,318,581 | |||||
Total liabilities and stockholders' equity | $ | 2,823,202 | $ | 2,566,085 | |||
Illumina, Inc. | |||||||||||||||||||
Condensed Consolidated Statements of Income | |||||||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||||||
(unaudited) | |||||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||||
June 30, 2013 | July 1, 2012 | June 30, 2013 | July 1, 2012 | ||||||||||||||||
Revenue: | |||||||||||||||||||
Product revenue | $ | 313,497 | $ | 258,839 | $ | 609,667 | $ | 514,475 | |||||||||||
Service and other revenue | 32,597 | 21,768 | 67,385 | 38,902 | |||||||||||||||
Total revenue | 346,094 | 280,607 | 677,052 | 553,377 | |||||||||||||||
Cost of Revenue: | |||||||||||||||||||
Cost of product revenue (a) | 98,150 | 74,911 | 188,128 | 155,062 | |||||||||||||||
Cost of service and other revenue (a) | 15,951 | 9,656 | 31,089 | 18,221 | |||||||||||||||
Amortization of acquired intangible assets | 8,584 | 3,043 | 15,134 | 6,086 | |||||||||||||||
Total cost of revenue | 122,685 | 87,610 | 234,351 | 179,369 | |||||||||||||||
Gross profit | 223,409 | 192,997 | 442,701 | 374,008 | |||||||||||||||
Operating Expenses: | |||||||||||||||||||
Research and development (a) | 67,608 | 71,223 | 129,058 | 120,062 | |||||||||||||||
Selling, general and administrative (a) | 88,700 | 68,516 | 173,774 | 136,485 | |||||||||||||||
Legal contingencies | 9,516 | - | 115,369 | - | |||||||||||||||
Acquisition related (gain) expense, net | (5,725 | ) | 1,080 | (1,904 | ) | 2,817 | |||||||||||||
Unsolicited tender offer related expense | 4,811 | 6,694 | 12,295 | 14,786 | |||||||||||||||
Headquarter relocation | (1,507 | ) | 1,830 | (750 | ) | 3,970 | |||||||||||||
Restructuring | - | 674 | - | 3,296 | |||||||||||||||
Total operating expenses | 163,403 | 150,017 | 427,842 | 281,416 | |||||||||||||||
Income from operations | 60,006 | 42,980 | 14,859 | 92,592 | |||||||||||||||
Other expense, net | (10,646 | ) | (8,193 | ) | (13,061 | ) | (17,532 | ) | |||||||||||
Income before income taxes | 49,360 | 34,787 | 1,798 | 75,060 | |||||||||||||||
Provision for (benefit from) for income taxes | 13,483 | 11,386 | (11,492 | ) | 25,457 | ||||||||||||||
Net income | $ | 35,877 | $ | 23,401 | $ | 13,290 | $ | 49,603 | |||||||||||
Net income per basic share | $ | 0.29 | $ | 0.19 | $ | 0.11 | $ | 0.40 | |||||||||||
Net income per diluted share | $ | 0.26 | $ | 0.18 | $ | 0.10 | $ | 0.37 | |||||||||||
Shares used in calculating basic net income per share | 124,362 | 123,214 | 124,065 | 122,928 | |||||||||||||||
Shares used in calculating diluted net income per share | 139,377 | 133,011 | 137,645 | 133,435 | |||||||||||||||
(a) Includes total stock-based compensation expense for share-based awards: | |||||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||||
June 30, 2013 | July 1, 2012 | June 30, 2013 | July 1, 2012 | ||||||||||||||||
Cost of product revenue | $ | 1,444 | $ | 1,844 | $ | 2,886 | $ | 3,656 | |||||||||||
Cost of service and other revenue | 157 | 168 | 311 | 185 | |||||||||||||||
Research and development | 8,954 | 7,687 | 16,960 | 15,114 | |||||||||||||||
Selling, general and administrative | 13,897 | 14,348 | 28,514 | 28,121 | |||||||||||||||
Stock-based compensation expense before taxes | $ | 24,452 | $ | 24,047 | $ | 48,671 | $ | 47,076 | |||||||||||
Illumina, Inc. | ||||||||||||||||
Condensed Consolidated Statements of Cash Flows | ||||||||||||||||
(In thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, 2013 | July 1, 2012 | June 30, 2013 | July 1, 2012 | |||||||||||||
Net cash provided by operating activities | $ | 88,606 | $ | 96,329 | $ | 176,446 | $ | 161,769 | ||||||||
Net cash provided by (used in) investing activities | 247,477 | (9,648 | ) | 182,456 | (151,518 | ) | ||||||||||
Net cash provided by (used in) financing activities | 5,784 | (30,264 | ) | (7,222 | ) | 3,352 | ||||||||||
Effect of exchange rate changes on cash and cash equivalents | (1,338 | ) | (199 | ) | (2,050 | ) | (169 | ) | ||||||||
Net increase in cash and cash equivalents | 340,529 | 56,218 | 349,630 | 13,434 |